

Stress Ulcer Prophylaxis: When, What Drug and How Long?

Leo Garcia, Pharm.D.

References:

1. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. *Am J Gastroenterol* 2000;95(11):3118-3122.
2. Wadibia EC, Lucas BD, Hilleman DE, et al. Economic impact of inappropriate histamine₂-receptor antagonist use. *Clin Ther* 1997;19(5):1085-1091.
3. Gullotta R, Ferraris L, Cortelezzi C, et al. Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study. *Ital J Gastroenterol Hepatol* 1997;29(4):325-329.
4. Smythe MA, Zarowitz BJ. Changing perspectives of stress gastritis prophylaxis. *Ann Pharmacother* 1994;28(9):1073-1085.
5. O'Keefe G, Maier RV. Current management of patients with stress ulceration. *Adv Surg* 1997;30:155-177.
6. Navab F, Steingrub J. Stress ulcer: is routine prophylaxis necessary? *Am J Gastroenterol* 1995;90(5):708-712.
7. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. *N Engl J Med* 1994;330(6):377-381.
8. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. *Am J Health-Syst Pharm* 1999;56(4):347-379.
9. Estruch R, Pedrol E, Castells A, et al. Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general medicine ward. *Scan J Gastroenterol.* 1991;26(8):819-826.
10. Levy MJ, Seelig CB, Robinson NJ, et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. *Dig Dis Sci* 1997;42(6):1255-1259.
11. Phillips JO, Metzler MH, Palmieri TL, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. *Crit Care Med* 1996;24(11):1793-1800.
12. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. *J Trauma* 1998;44(3):527-533.
13. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. *JAMA* 1996;275(4):308-314.
14. Cook DJ, Reeve BK, Scholes LC. Histamine-2-receptor antagonists and antacids in the critically ill population: stress ulceration versus nosocomial pneumonia. *Infect Control Hosp Epidemiol* 1994;15(7):437-442.
15. Tryba M. Prophylaxis of stress ulcer bleeding: a meta-analysis. *J Clin Gastroenterol* 1991;13(suppl 2):S44-S55.
16. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. *N Engl J Med* 1998;338(12):791-797.
17. Tarnawski A, Hollander D, Gergely H. The mechanism of protective, therapeutic, and prophylactic actions of sucralfate. *Scand J Gastroenterol* 1987;22(suppl 140):7-13.
18. Heyland DK, Tougas G, King D, et al. Impaired gastric emptying in mechanically ventilated, critically ill patients. *Intensive Care Med* 1996;22(12):1339-1344.
19. Dive A, Moulart M, Jonard P, et al. Gastrointestinal motility in mechanically ventilated critically ill patients: A manometric study. *Crit Care Med* 1994;22(3):441-447.
20. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? *Gastroenterology* 1994;106(1):60-64.

(Continued on page 42)

A University of Washington / Harborview Medical Center Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2002 by the University of Washington
Also published on the World Wide Web at <http://uw.prnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.

Stress Ulcer Prophylaxis: When, What, How Long? (cont.)**References**
(cont.)

21. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H₂RA therapy on nocturnal gastric acid breakthrough. *Gastroenterology* 2002;122(3):625-632.
22. Wade EE, Rebuck JA, Healey MA, et al. H₂ antagonist-induced thrombocytopenia: is this a real phenomenon? *Intensive Care Med* 2002;28(4):459-465.
23. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. *NEngl J Med* 1987;317(22):1376-1382.
24. Cook DJ, Laine LA, Guyatt GH, et al. Nosocomial pneumonia and the role of gastric pH: a meta-analysis. *Chest* 1991;100(1):7-13.
25. Tryba M. Sucralfate versus antacids or H₂-antagonists for stress ulcer prophylaxis: A meta-analysis on efficacy and pneumonia rate. *Crit Care Med* 1991;19(7):942-949.
26. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. *Drugs* 1997;54(4):581-596.
27. Pitimana-aree S, Forrest D, Brown G, et al. Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care. *Intensive Care Med* 1998;24(3):217-223.
28. MacLaren R, Jarvis CL, Fish DN. Use of enteral nutrition for stress ulcer prophylaxis. *Ann Pharmacother* 2001;35(12):1614-1623.
29. Lam NP, Le PT, Crawford SY, et al. National survey of stress ulcer prophylaxis. *Crit Care Med* 1999;27(1):98-103.